aim cysteinyl leukotrienes important mediators pathogenesis asthma leukotriene c4 synthase key enzyme biosynthesis aim evaluate responsiveness leukotriene receptor antagonists determined expression variant c polymorphism enzyme methods carried retrospective analysis NUMBER randomised trials performed department asthmatics trials effect leukotriene receptor antagonist compared placebo primary outcome bronchial hyperresponsiveness adenosine monophosphate methacholine secondary outcomes forced expiratory volume NUMBER second exhaled nitric oxide peripheral blood eosinophils results primary outcome attenuation bronchial hyperresponsiveness leukotriene receptor antagonist vs placebo significant effects genotype adenosine monophosphate amp n NUMBER NUMBER improvements aa respectively methacholine n NUMBER NUMBER improvements respectively significant differences genotypes aa vs geometric mean NUMBER 95ci NUMBER 95ci amp methacholine respectively differences genotypes secondary outcomes conclusion polymorphisms leukotriene c4 synthase did determine responsiveness terms attenuation bronchial hyperresponsiveness leukotriene receptor antagonists asthmatics prospective large pharmacogenetic studies required severe patients greater improvements pharmacodynamic outcome measures bronchial hyperresponsiveness exhaled nitric oxide pro inflammatory wild type placebo controlled mild moderate NUMBER fold NUMBER fold fold differences NUMBER NUMBER NUMBER NUMBER mild moderate ac cc ac cc